Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the Price/FCF ratio high or low?
The Price/FCF ratio of 21.34 is 16% above its 5-year average of 18.40, near the high end of its 5-year range (13.38–23.15).
29.69% above its 12-month average of 16.46.
Reported annual fiscal-period values; no daily interpolation.
PRICE/FCF RATIO
21.34
PRICE/FCF RATIO AVG TTM
16.46
PRICE/FCF RATIO AVG 3Y
16.82
PRICE/FCF RATIO AVG 5Y
18.40
PRICE/FCF RATIO AVG 10Y
17.32
PRICE/FCF RATIO AVG 15Y
16.22
PRICE/FCF RATIO AVG 20Y
16.81
CURRENT VS TTM AVG
+29.69%
CURRENT VS 3Y AVG
+26.87%
CURRENT VS 5Y AVG
+15.95%
CURRENT VS 10Y AVG
+23.24%
CURRENT VS 15Y AVG
+31.55%
CURRENT VS 20Y AVG
+26.94%
SECTOR MEDIAN · HEALTHCARE
22.81
median of 81 covered companies
CURRENT VS SECTOR MEDIAN
-6.44%
vs the sector median at left
Roche Holding AG
Market Cap
$359.46B
Price/FCF Ratio
21.34
TTM Avg
16.46
3Y Avg
16.82
5Y Avg
18.40
Market Cap
$358.76B
Price/FCF Ratio
15.15
TTM Avg
16.57
3Y Avg
26.69
5Y Avg
23.97
Market Cap
$369.34B
Price/FCF Ratio
23.56
TTM Avg
20.07
3Y Avg
20.80
5Y Avg
21.23
Market Cap
$234.38B
Price/FCF Ratio
31.97
TTM Avg
31.31
3Y Avg
29.51
5Y Avg
30.82
Market Cap
$193.04B
Price/FCF Ratio
22.81
TTM Avg
27.23
3Y Avg
32.99
5Y Avg
29.57
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 21.34 | 16.46 | 16.82 | 18.40 |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 15.15 | 16.57 | 26.69 | 23.97 |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 23.56 | 20.07 | 20.80 | 21.23 |
| AbbVie Inc. (ABBV)vs › | $455.87B | 23.66 | 20.38 | 17.77 | 15.22 |
| AstraZeneca PLC (AZN)vs › | $255.15B | 29.68 | 32.09 | 31.69 | 33.74 |
| Amgen Inc. (AMGN)vs › | $235.85B | 23.54 | 19.41 | 19.98 | 18.23 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 31.97 | 31.31 | 29.51 | 30.82 |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 28.10 | 33.63 | 43.31 | 39.00 |
| Abbott Laboratories (ABT)vs › | $193.04B | 22.81 | 27.23 | 32.99 | 29.57 |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | 13.95 | 16.77 | 14.12 | 12.45 |
P/FCF Ratio
21.3
FCF Yield
4.69%
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2025-12-31 | 19.53 |
| 2024-12-31 | 13.38 |
| 2023-12-31 | 17.01 |
| 2022-12-31 | 17.36 |
| 2021-12-31 | 20.00 |
| 2020-12-31 | 23.15 |
| 2019-12-31 | 14.26 |
| 2018-12-31 | 13.11 |
| 2017-12-31 | 14.54 |
| 2016-12-31 | 18.23 |
| 2015-12-31 | 19.91 |
| 2014-12-31 | 17.70 |
| 2013-12-31 | 16.20 |
| 2012-12-31 | 12.22 |
| 2011-12-31 | 12.62 |
| 2010-12-31 | 10.33 |
| 2009-12-31 | 10.98 |
| 2008-12-31 | 16.36 |
| 2007-12-31 | 22.89 |
| 2006-12-31 | 30.03 |
| 2005-12-31 | 26.44 |
| 2004-12-31 | 23.23 |
| 2003-12-31 | 22.04 |
| 2001-12-31 | 19.66 |
| 2000-12-31 | 53.84 |
| 1998-12-31 | 95.28 |
